BMY Stock Recent News

Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.

Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.

PRINCETON, N.J.--(BUSINESS WIRE)--Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development.

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Pfizer (NYSE: PFE) surged 8.24% over the past month, reducing the stock’s year-to-date loss to 5.02%. Over the past year, PFE has fallen by 8.75%. Recently, the FDA announced it will only be recommending COVID-19 vaccines for seniors aged 65 and older and those with certain medical conditions, excluding healthy adults and children above a certain age from its recommendation. That may act as a severe headwind for Pfizer, whose coronavirus franchise — Paxlovid and Comirnaty — contributed $11.1 billion in combined revenue in 2024. Pfizer continues to search for its footing in 2025 despite strong year-end 2024 results driven by stronger-than-expected sales from its COVID products, as well as its non-COVID products, such as Vyndaquel, Padcev and Eliquis. The 176-year-old Big Pharma mainstay has been at the forefront of its industry for several decades. Long known for its mass production of santonin (an antiparasitic drug), penicillin, and antibiotics, the latter part of

Key Points Altria (NYSE: MO) and Bristol Myers Squibb (NYSE: BMY) are highlighted as strong dividend plays yielding over 7% and 5% respectively, offering income stability even amid moderate price underperformance. Telecom giants AT&T (NYSE: T) and Verizon (NYSE: VZ) are regaining favor as pure-play wireless providers with attractive yields near 6%, especially as both exit non-core ventures. Douglas and Lee emphasize trimming positions after strong runs and reinvesting selectively, noting that blue-chip dividend stocks currently outperforming the S&P 500 may revert to historical norms. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don’t waste another minute; get started by clicking here.(Sponsor) Watch the Video document.createElement('video'); https://videos.247wallst.com/247wallst.com/2025/07/

Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.

Bristol Myers Squibb (BMY) closed at $48.02 in the latest trading session, marking a +2.85% move from the prior day.